Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan

ecancermedicalscience

Volumn 8, Issue , 2014, Pages

  Bouche, Gauthier ^a   André, Nicolas ^b,o,u   Banavali, Shripad ^c   Berthold, Frank ^d   Berruti, Alfredo ^e   Bocci, Guido ^f   Brandi, Giovanni ^g   Cavallaro, Ugo ^h   Cinieri, Saviero ⁱ   Colleoni, Marco ^h   Curigliano, Giuseppe ^h   Di Desidero, Teresa ^f   Eniu, Alexandru ^j   Fazio, Nicola ^h   Kerbel, Robert ^k   Hutchinson, Lisa ^l   Ledzewicz, Urszula ^m   Munzone, Elisabetta ^h   Pasquier, Eddy ^b,n,o   Scharovsky, O Graciela ^p   Shaked, Yuval ^q   Štěrba, Jaroslav ^r   Villalba, Martin ^s,t   Bertolini, Francesco ^h   more..

^a Anticancer Fund   (Belgium)

^b Metronomics Global Health Initiative   (France)

^c TATA MEMORIAL HOSPITAL   (India)

^d UNIVERSITY OF COLOGNE   (Germany)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ Medical Oncology Division   (Italy)

^j Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^k UNIVERSITY OF TORONTO   (Canada)

^l Nature Reviews Clinical Oncology   (United Kingdom)

^m SOUTHERN ILLINOIS UNIVERSITY EDWARDSVILLE   (United States)

ⁿ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^o University of the Mediterranean Aix Marseille II   (France)

^p UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^q TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^r UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^s INSERM   (France)

^t MONTPELLIER UNIVERSITY HOSPITAL   (France)

^u TIMONE HOSPITAL   (France)

more..

Author keywords

Adult; Anti angiogenesis; Cancer; Child; Drug repurposing; Metronomic chemotherapy; Pharmacoeconomics

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CELECOXIB; CYCLOPHOSPHAMIDE; ETOPOSIDE; FENOFIBRATE; GEMCITABINE; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; RETINOIC ACID; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB; UFT; VITAMIN D;

ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER MODEL; CHILDHOOD CANCER; CONFERENCE PAPER; HUMAN; METRONOMIC DRUG ADMINISTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84907386346     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.463     Document Type: Conference Paper

References (58)

1. Klement G et al (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity The J Clini Invest 105(8) pp R15-24 DOI: 10.1172/JCI8829
2. Browder T et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res 60(7) pp 1878-86 PMID: 10766175
3. Hanahan D, Bergers G and Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice J Clin Invest 105(8) pp 1045-7 DOI: 10.1172/JCI9872 PMID: 10772648 PMCID: 300842
4. Pasquier E, Kavallaris M and André N (2010) Metronomic chemotherapy: new rationale for new directions Nat Rev Clin Oncol 7(8) pp 455-65 DOI: 10.1038/nrclinonc.2010.82 PMID: 20531380
5. André N, Carré M and Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11(7) pp 413-31 DOI: 10.1038/nrclinonc.2014.89 PMID: 24913374
6. Shaked Y et al (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors Science 313(5794) pp 1785-7 DOI: 10.1126/science.1127592 PMID: 16990548
7. Bertolini F et al (2003) Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells Cancer Res 63(15) pp 4342-6 PMID: 12907602
8. Pietras K and Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer J Clin Oncol 23(5) pp 939-52 DOI: 10.1200/JCO.2005.07.093
9. Shaked Y et al (2005) Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy Cancer Res 65(16) pp 7045-51 DOI: 10.1158/0008-5472.CAN-05-0765 PMID: 16103050
10. Hasnis E et al (2014) Anti-bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy Neoplasia 16(6) pp 501-10 DOI: 10.1016/j.neo.2014.05.011 PMID: 24957319
11. Orlando L et al (2006) Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer BMC Cancer 6 p 225 DOI: 10.1186/1471-2407-6-225 PMID: 16978400 PMCID: 1579231
12. Watanabe T et al (2009) Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial J Cclinic Oncol 27(9) pp 1368-74 DOI: 10.1200/JCO.2008.18.3939
13. Bottini A, Generali D, Brizzi MP and Fox SB et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients J Clin Oncol 24 3623-8 PMID: 16877730
14. Ge Y et al (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome Cancer Immunol Immunother 61(3) pp 353-62 DOI: 10.1007/s00262-011-1106-3
15. Masuda N et al (2014) A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer Cancer Chemother Pharmacol 74(2) pp 229-38 DOI: 10.1007/s00280-014-2492-y PMID: 24871032
16. Brandi G et al Durable complete response of hepatocellular carcinoma after metronomic capecitabine Tumori 96(6) pp 1028-30 PMID: 21388070
17. Brandi G et al (2013) Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study Oncologist 18(12) pp 1256-7 DOI: 10.1634/theoncologist.2013-0093 PMID: 24232581 PMCID: 3868418
18. Agrawal A et al (2014) Response assessment in metronomic chemotherapy: RECIST or PERCIST? Indian J Nucl Med?29(2) pp 74-80 DOI: 10.4103/0972-3919.130285 PMID: 24761057 PMCID: 3996775
19. Zapletalova D et al (2012) Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience Oncology 82(5) pp 249-60 DOI: 10.1159/000336483 PMID: 22538363
20. Ledzewicz U and Schättler H (2014) On optimal chemotherapy for heterogeneous tumors J Biological Systems 22 1-21 DOI: 1142/S0218339014400014
21. Ledzewicz U and Schaettler H (2008) Optimal and suboptimal protocols for a class of mathematical models of tumor antiangiogenesis J Theoretical Biol 252 295-312 DOI: 10.1016/j.jtbi2008.02.014
22. Ledzewicz U, Naghneian M and Schaettler H (2011) Optimal Response to Chemotherapy for a Mathematical Model of Tumor-Immune Dynamics J Math Biol 64 557-77 DOI: 10.1007/s00285-011-0424-6
23. Buyse M et al (2010) Biomarkers and surrogate end points - the challenge of statistical validation Nat Rev Clin Oncol 7(6) pp 309-17 DOI: 10.1038/nrclinonc.2010.43 PMID: 20368727
24. Stempak D et al (2006) A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors J Pediatr Hematol Oncol 28(11) pp 720-8 DOI: 10.1097/01.mph.0000243657.64056.c3 PMID: 17114958
25. Allegrini G et al (2008) A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients Br J Cancer 98(8) pp 1312-9 DOI: 10.1038/sj.bjc.6604311 PMID: 18362940 PMCID: 2361703
26. Allegrini G et al (2012) Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers Angiogenesis 15(2) pp 275-86 DOI: 10.1007/s10456-012-9260-6 PMID: 22382585 PMCID: 3338912
27. Orlandi P et al (2013) VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide Br J Cancer 109(4) pp 957-64 DOI: 10.1038/bjc.2013.398 PMID: 23860526 PMCID: 3749570
28. Fontana A et al (2009) Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer Clin Cancer Res 15(15) pp 4954-62 DOI: 10.1158/1078-0432.CCR-08-3317 PMID: 19622584
29. Marchetti V et al (2012) First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study Invest New Drugs 30(4) pp 1725-30 DOI: 10.1007/s10637-011-9672-y
30. André N (2013) Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 14(6) pp. e239-48 DOI: 10.1016/S1470-2045(13)70056-1 PMID: 23639324
31. Ghosh J et al (n.d.) Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India Indian J Cancer 48(4) pp 391-6 PMID: 22293249
32. Pai PS et al Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis Indian J Cancer 50(2) pp 135-41 PMID: 23979205
33. Traore F (2011) Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01 J Pediatr Hematol Oncol 33(1) pp 31-4 DOI: 10.1097/MPH.0b013e3182018ab8
34. Traore F et al (2013) Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02 Indian J Cancer 50(3) pp. 250-3 DOI: 10.4103/0019-509X.118741 PMID: 24061467
35. Mercurio S et al (2013) Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma Acta Neuropathol Commun 1(1) p 17 DOI: 10.1186/2051-5960-1-17 PMID: 24252689 PMCID: 3893468
36. Pasquier E et al (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment Oncotarget 2(10) pp 797-809 PMID: 22006582 PMCID: 3248157
37. Pasquier E et al (2013) B-Blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma Br J Cancer 108(12):2485-94 DOI: 10.1038/bjc.2013.205 PMID: 23695022 PMCID: 3694229
38. Xu T et al (2013) Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice J Ped Surg 48(12) pp 2460-5 DOI: 10.1016/j.jpedsurg.2013.08.022
39. Wolter JK et al (2014) Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma Oncotarget 5(1) pp 161-72 PMID: 24389287 PMCID: 3960198
40. Peyrl A et al (2012) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors Pediatr Blood Cancer 59(3) pp 511-7 DOI: 10.1002/pbc.24006
41. Sterba J et al (2006) Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study Onkologie 29(7) pp 308-13 DOI: 10.1159/000093474 PMID: 16874014
42. Villalba M et al (2013) From tumor cell metabolism to tumor immune escape Int J Biochem Cell Biol 45(1) pp 106-13 DOI: 10.1016/j.biocel.2012.04.024 PMID: 22568930
43. Villalba M et al (2014) Chemical metabolic inhibitors for the treatment of blood-borne cancers Anticancer Agents Med Chem 14(2) pp 223-32 PMID: 24237221
44. Fazio N et al (2010) Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas Cancer Treat Rev 36 (Suppl 3) pp S87-94 DOI: 10.1016/S0305-7372(10)70026-8 PMID: 21129617
45. Brizzi MP et al (2009) Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network BMC Cancer 9 pp 388 DOI: 10.1186/1471-2407-9-388 PMID: 19886987 PMCID: 2776604
46. Berruti A et al (2014) Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study BMC Cancer 14(14) pp184 DOI: 10.1186/1471-2407-14-184 PMID: 24628963 PMCID: 3996907
47. Koumarianou A et al (2012) Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours Endocr-Relat Cancer 19(1) pp L1-4 DOI: 10.1530/ERC-11-0287 PMID: 22232542 PMCID: 3255566
48. Terzolo M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma N Eng J Med 356(23) pp 2372-80 DOI: 10.1056/NEJMoa063360
49. Sperone P et al (2010) Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study Endocr-Relat Cancer 17(2) pp 445-53 DOI: 10.1677/ERC-09-0281 PMID: 20410174
50. Berruti A et al (2012) Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma Eur J Endocrinol E 166(3) pp 451-8 DOI: 10.1530/EJE-11-0918
51. Maddaluno L et al (2009) The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells J Exp Med 206(3) pp 623-35 DOI: 10.1084/jem.20081211 PMID: 19273627 PMCID: 2664975
52. Pantziarka P et al (2014) The Repurposing Drugs in Oncology (ReDO) Project Ecancermedicalscience 8 pp 442
53. Pantziarka P et al (2014) Repurposing Drugs in Oncology (ReDO) - mebendazole as an anti-cancer agent Ecancermedicalscience 8 pp 443 PMID: 25075217 PMCID: 4096024
54. Rico MJ et al (2014) Comparative effectiveness of two metronomic chemotherapy schedules-our experience in the preclinical field Cancer Invest 32(3) pp 92-8 DOI: 10.3109/07357907.2013.877480 PMID: 24499110
55. Perroud HA et al (2013) Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients Future Oncol 9(3) pp 451-62 DOI: 10.2217/fon.12.196
56. Perroud HA and Rico et al Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer Indian J Cancer 50(2) pp 115-21 PMID: 23979202
57. Patil V et al (2012) Metronomic chemotherapy in advanced oral cancers J Cancer Res Ther 8 (Suppl 1) pp S106-10
58. Patil V et al (2013) Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers Clinic Oncol (R Coll Radiol) 25(6) pp 388 DOI: 10.1016/j.clon.2013.01.002